Indeed, AD patients treated with AChE inhibitors show a reduced risk of hip fracture and improved bone healing, suggesting that impaired parasympathetic signaling affects bone homeostasis and may be a potential target for improving bone health in these patients. This evidence concerns the gene ACHE and Alzheimer disease.